NC-ARETEIA-THERAPEUTICS
7.9.2022 13:28:36 CEST | Business Wire | Press release
Areteia Therapeutics, Inc. (“Areteia”) today announced that its Board of Directors has appointed Ian Read as Chairman of the Board. Mr. Read’s appointment as Areteia’s first Chairman follows the launch of the Company by Knopp Biosciences and Population Health Partners and the successful completion of the Company’s $350 million Series A financing led by Bain Capital Life Sciences, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.
“I am excited that Ian has been appointed as Chairman,” said Jorge Bartolome, Chief Executive Officer of Areteia. “He is an incredibly esteemed executive whose depth of experience, proven leadership and expert judgment will be invaluable to me and the Board of Directors as we focus on delivering on the Company’s strategy and advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”
Commenting on his appointment, Mr. Read said, “I am honored to be chosen to serve as Chairman of Areteia and look forward to working with Jorge and the team. This is a compelling opportunity to address a high unmet need for severe asthmatics by bringing a new oral medicine to market to potentially treat eosinophilic asthma earlier in the treatment paradigm and offer patients and health systems an alternative to injectable biologics.”
Mr. Read brings to his role a distinguished 42-year track record as one of the foremost leaders, dealmakers, and value creators in the global biopharmaceutical industry. He was Chairman and Chief Executive Officer of Pfizer, Inc. from December 2010 until January 2019, and Executive Chairman until December 2019. During that tenure, he oversaw over 30 new drug approvals, $88 billion in acquisition and divestiture deals, and a total shareholder return of 250%—representing over $242 billion in value creation. Mr. Read oversaw a period of industry-shaping innovation regarding the structure of Pfizer and its portfolio, including novel spin-outs and acquisitions alongside dozens of major licensing agreements. Mr. Read currently serves as a partner of Population Health Partners.
About Areteia Therapeutics
Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development, including Phase III clinical trials of dexpramipexole, in partnership with Population Health Partners’ development unit, Validae Health.
About Dexpramipexole
Dexpramipexole is an oral small molecule in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.
About Eosinophilic Asthma
Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005177/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bridger Photonics Posts Record Year as Operators Turn to Trusted Emissions Intelligence4.2.2026 13:20:00 CET | Press release
Bridger Photonics (“Bridger”) closed its strongest year in company history last year, marked by record asset coverage, record revenue, and global adoption of its methane emissions data and intelligence across multiple continents and the entire oil and natural gas value chain. Bridger’s momentum reflects a clear shift in how operators choose to manage emissions: away from legacy and weather-limited approaches and toward entire asset coverage with data they can trust. Bridger continues to lead the methane detection space—growing existing customers and attracting new ones. Bridger has competitively displaced 32 customers from other aerial technologies, driven by deep industry expertise, proven data reliability and actionability, the ability to operate across challenging conditions and seasons, close coordination with ground crews, and a white-glove service model designed around operator needs. Customers across onshore production, midstream, LNG, and offshore operations are increasingly re
Registrar Corp Acquires TechniCAL and Becomes the Global Compliance Leader in Shelf-stable Packaged Foods Safety4.2.2026 13:00:00 CET | Press release
Registrar Corp, the world’s largest food and beverage regulatory compliance provider, today announced its acquisition of TechniCAL, the world’s leading independent Process Authority for low-acid and acidified foods. Registrar Corp is a Paine Schwartz Partners portfolio company. Consumer demand for convenience and longer product life without refrigeration has driven rapid growth in shelf-stable foods and beverages, with packaging innovations extending beyond cans and glass jars to formats such as retort pouches and cartons. Ensuring products in these various packaging formats are safe from harmful microorganisms is critical to public health and required by the U.S. FDA. Together, Registrar Corp and TechniCAL provide the industry’s most complete solution, combining proven scientific expertise, regulatory knowledge, training, and advanced thermal testing. “TechniCAL is world renowned for its Process Authority expertise and advanced testing technologies assuring compliant thermal processin
Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid4.2.2026 13:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable under the rules of the Toronto Stock Exchange (the “TSX”). The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential dec
Morgan Stanley Inclusive & Sustainable Ventures Hosts Global Demo Day, Opens Applications for Next Cohort4.2.2026 13:00:00 CET | Press release
Morgan Stanley (NYSE: MS) today is hosting its annual global Inclusive & Sustainable Ventures (MSISV) Demo Day, with startups and nonprofits participating from across the Americas, Europe, the Middle East and Africa (EMEA). The organizations will pitch over 300 investors, as well as potential business partners and customers. Over the past five months, MSISV has supported 29 startups and four nonprofits through an intensive accelerator program, providing them with capital, a tailored curriculum, mentorship opportunities and business-growth resources from Morgan Stanley’s ecosystem of internal and external partners. “With founders spanning 10 countries and 13 industries, our Morgan Stanley Inclusive & Sustainable Ventures cohort underscores the potential of innovators globally to bring disruptive solutions for business and society to market,” said Jessica Alsford, Morgan Stanley Chief Sustainability Officer. “We are eager to watch as these founders continue to scale with the backing of o
Macrobond Launches Macrobond Amplify, A New Standard for Interactive Financial Research4.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, announced the launch of Macrobond Amplify, a browser-based research distribution tool that enables economists and analysts to deliver rich, interactive content to their consumers at scale. Amplify empowers analysts and research teams to move beyond static charts and PDFs, delivering interactive, explorable insights that build trust, foster collaboration, and drive better decision-making. With Amplify, research teams can publish interactive, auditable research models that clients can explore directly through charts and dynamic visualizations. By sharing a simple link, Amplify users can distribute their research at scale with both internal partners and clients. “As the research industry evolves, analysts and economists face growing pressure to ensure their work reaches the right audiences, shows transparency, and demonstrates the rigour behind their thinking,” says Dan Seal, Chief Product Officer at Macrobond. “Amplify
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom